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Abstract:  The immune response plays an important role in the pathophysiology of 
numerous diseases including asthma, autoimmunity and cancer. Application of biomarkers 
of immunotoxicity in epidemiology studies and human clinical trials can improve our 
understanding of the mechanisms that underlie the associations between environmental 
exposures and development of these immune-mediated diseases. Immunological 
biomarkers currently used in environmental health studies include detection of key 
components of innate and adaptive immunity (e.g., complement, immunoglobulin and cell 
subsets) as well as functional responses and activation of key immune cells. The use of 
high-throughput assays, including flow cytometry, Luminex, and Multi-spot cytokine 
detection methods can further provide quantitative analysis of immune effects. Due to the 
complexity and redundancy of the immune response, an integrated assessment of several 
components of the immune responses is needed. The rapidly expanding field of 
immunoinformatics will also aid in the synthesis of the vast amount of data being 
generated. This review discusses and provides examples of how the identification and 
development of immunological biomarkers for use in studies of environmental exposures 
and immune-mediated disorders can be achieved.  
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1. Introduction 
The field of immunotoxicology has rapidly expanded and the main drivers for this development 
include recognition that environmental chemicals can alter immune response and function, increase in 
immune-mediated diseases (asthma, allergies, type 1 diabetes, rheumatoid arthritis, etc.) [1-4], and 
recognition that the immune system plays an important role in the pathophysiology of other disease 
states such as cancer [1] and atherosclerosis [2-4]. A pro-inflammatory immune response contributes 
to tissue and organ damage and is a common factor in many auto-immune diseases (e.g., Type 1 
diabetes, rheumatoid arthritis, systemic lupus erythermatosus) and other disorders (e.g., promotion of 
atherosclerotic plaques in cardiovascular disease). Conversely, the lack of an appropriate inflammatory 
immune response contributes to lowered immune surveillance and the progression of tumors and 
cancers. A thorough understanding of the role of the immune response in the pathophysiology of these 
diseases is important to identify efficacious therapies and effective interventions. Further, the 
prevention of these diseases can be aided when specific and sensitive biomarkers, particularly ones 
that precede clinical onset of these diseases, are identified.  
A biomarker is defined as “a characteristic that is evaluated as an indicator of normal biological or 
pathogenic processes, or a pharmacological response to a therapeutic intervention [5,6].” Biomarkers 
have been used for many years in toxicology and risk assessment and are often classified in terms of 
biomarkers of exposure, effect, and susceptibility [7]. However, categories based on intended roles and 
applications (e.g., disease, efficacy, mechanism, pharmacodynamic, and target) provide a useful 
classification system (see Baker et al. 2005 [8]). Disease-related biomarkers are mostly used for 
monitoring disease causality, progression, and susceptibility, and, to some extent, to identify strategies 
for patient stratification [9]. Both regulatory agencies and industry are keen to identify biomarkers that 
will aid in the early detection of toxicities [6,7,10,11]. 
2. Key Considerations for Developing Biomarkers of Immunotoxicity 
Development of disease biomarkers broadly involves the three stages of identification, validation, 
and application (see Figure 1) and key elements of the process include (1) identifying biomarkers that 
can establish relevance (i.e., related to the disease of exposure of interest), (2) strong, mechanistic 
molecular or biochemical basis in the pathophysiology of a disease, (3) sensitivity and specificity to 
treatment or exposure, (4) reliability (reproducibility, accuracy, precision, robustness), (5) practicality 
(level of assay invasiveness), and (6) simplicity in use and application [12,13]. Rarely does one 
biomarker meet all six requirements, however early consideration of these parameters in   
properly-designed and statistically powered studies can improve the final predictive value of 
biomarkers [14].  
Since the immune system is composed of multiple organs (e.g., bone marrow, thymus, spleen and 
lymph nodes) and an appropriate immune response involves the interaction of multiple cell types  
(e.g., dendritic, B, and T-helper cells) and pleiotropic components (e.g., immunoglobulin and 
cytokines) it is a challenge to identify a key parameter to develop as a biomarker. Immunotoxic effects 
are commonly categorized into one of four categories: immunosuppression (reduction in efficacy   
or activation of immune system), immunostimulation (general enhanced immune response), Int. J. Environ. Res. Public Health 2011, 8 1390 
 
hypersensitivity (specific immunostimulatory response mediated by immunoglobulins or T-cells), and 
autoimmunity (immune response against self). Immunotoxicity refers to any adverse effect on the 
structure or function of innate and adaptive immunity (see excellent references on this topic [15-18]). 
Figure 1. Key considerations in biomarker development: identification, validation, and application. 
 
The most common immune markers and sample types are summarized in Table 1. For example, 
cell-surface markers and antibodies are commonly used to evaluate the status of the immune system 
and can be detected using whole blood or serum and plasma by a multitude of methods. Although Int. J. Environ. Res. Public Health 2011, 8 1391 
 
blood collection is an invasive procedure, subjects are accustomed to blood draws. However, if the 
same biomarker can be detected in samples collected using a non-invasive procedure, such as saliva or 
urine, these could then be prioritized for development, particularly for studies intended for pediatric 
populations. Efforts to develop non-invasive collection methods include analysis of immune 
components in saliva [19,20] or induced sputum [21] and exhaled breath condensate [22]. 
Table 1. Biomarkers used to investigate immunotoxicity in human studies. 
Immune Markers  Examples of Endpoints  Biological Samples 
Cellular phenotype; 
activation markers 
CD3, CD4, CD8, CD11c, CD19, CD25, 
CD56, CD14, basophils, neutrophils; 
Activation markers: CD69, CD45RO, 
CD45RA 
Whole blood, Urine 
Antibodies  IgM, IgD, IgG, IgA, IgE,   Plasma, Breastmilk 
Cytokines  IL-2, IL-4, IL-5, IL-10, IL-13, IFN-γ, 
TNF-α, GM-CSF 
Serum/plasma, peripheral 
blood, urine, saliva 
Chemokines 
 
RANTES, IP-10, MIP-1α, MIP-1β,  
MDC, TARC 
Serum/plasma 
Proliferation Tests 
 
Mitogenic stimulation (PHA,  
Concavalin A, specific antigen) 
Peripheral blood 
3. Sample Collection and Analytical Methods 
Biomarker studies require processing and storage of numerous biological samples with the goals of 
obtaining a large amount of information and minimizing future research costs. An efficient study 
design includes provisions for processing of the original samples, such as separation of various 
components (e.g., serum, plasma, clot etc.), stabilization, cryopreservation, DNA isolation, and 
preparation of specimens for exposure assessment [23]. Standard operating procedures and quality 
control plans help to protect sample quality and to assure validity of the biomarker data. Data validity 
can also be affected by the sample type used. For example, proteomic profiles reportedly differ 
between serum and plasma samples [24] with less reproducibility observed with serum samples [25-27]. 
Cytokine levels may be lower in serum than in stimulated whole blood cultures [28,29]. The types of 
blood collection tubes (proteins adsorb to different materials) or anti-coagulants used (heparin and 
EDTA have different mechanisms for the prevention of clotting) also contribute to variability in the 
data obtained [30]. Also, the effect of transportation and storage of biological material must be 
examined very closely as the assay can be time- and temperature-sensitive. These factors, in addition 
to the assay and method variables listed above, can affect the precision of the measurement. Any 
significant contributor can then be controlled for in the large-scale epidemiology studies. 
Employment of high-throughput methods in large-scale epidemiology studies provide a number of 
advantages for study designs that involve the collection and timely analysis of numerous clinical 
samples. Flow cytometry has emerged as a powerful tool for quantitative, single-cell analysis of both 
surface markers and intracellular antigens. This platform can now be used to measure intracellular 
signaling cascades and phosphorylation events and are employed extensively in high-throughput drug 
screening. Multiplex detection of cytokines allows the simultaneous measurement of multiple Int. J. Environ. Res. Public Health 2011, 8 1392 
 
cytokines in a sample [31]. These platforms increase the efficiency of measuring the cytokines while 
reducing the serum sample volumes required for the testing, thus replacing the more traditional 
ELISA-based approach. Compared to Cytokine Bead Array (CBA), Luminex kits were found to be 
highly reproducible and reliable [32]. Increased standardization between laboratories represents 
another challenge in the application of immune biomarkers. However, this is one that can be remedied 
with increased collaboration and exchange of information during which protocols and methods are 
shared across laboratories and the reproducibility of immune marker detection can be determined 
before the samples are analyzed. Variability in parameters measured by flow cytometry attributable to 
subjective gating and/or determination of positive versus negative events can be reduced by 
distributing templates for acquisition and data analysis among the sites involved in analysis [33].  
4. Case Studies: Asthma and Chronic Obstructive Pulmonary Disease (COPD) 
Application of these methods will be illustrated with examples from the field of asthma and chronic 
obstructive pulmonary disease (COPD), two of the most common disorders of the airways. In both 
cases, airway obstruction is the result of chronic inflammation and the infiltration of pro-inflammatory 
cells and mediators [34,35]. However, there are some noteworthy differences in the histopathology and 
the immune cells recruited for these two diseases [36]. The immune profiles of these diseases are 
summarized in Table 2 and, although there is a strong association between these immunologic 
endpoints and disease status, the predictive value of these endpoints are still under investigation.  
Table 2. Findings from selected biomarker studies on the relationship between 
environmental exposures and health outcomes. 
  Description of Epidemiology 
Study Design & Subjects 
Method of exposure 
assessment 
Biological sample  
and (immune  
biomarkers employed) 
Key findings and evaluation  
of concordance 
Atopy Longitudinal/Prospective;   
(n = 3,062), combined birth 
cohorts (ages 1–8 years) 
Questionnaire;  
indoor environment, 
pet exposure 
Peripheral blood  
(total and specific IgE 
and CD14/IL13  
genotypes) 
Atopy influenced by IL13 in  
<8 years and CD14 with pet 
interaction in ages 4 and 8  
(Bottema et al. 2008) [37] 
 Longitudinal;  birth  cohort 
(n = 172) 
 Peripheral  blood 
(differential cell counts 
and IFN-γ, TNF-α,  
IL-4, IL-5, IL-9, Il-10, 
IL-13 by ELISA) 
Atopy associated with increased 
Th2; bronchial hyperresponsiveness 
associated with Th1  
(Heaton et al. 2005) [38] 
 Cross-sectional;  children   
ages 6–16 (n = 24) vs. 
reference group 
Questionnaire; 
parental tobacco 
smoke 
Nasopharangeal 
aspirate (analyzed for 
IL-13 cytokine levels) 
ETS augments secretion of IL-13 
(Feleszko et al. 2006) [39] 
Asthma Longitudinal/Prospective;   
birth cohort (n = 239) 
Questionnaire; 
pesticide and 
allergen exposures 
Peripheral blood 
(intracellular IFN-γ  
and IL-4 in  
T-helper cells) 
Th2 cells associated with asthma  
and wheeze; Th1 associated with 
breastfeeding and parental 
occupation in agriculture  
(Duramad et al. 2006) [40] Int. J. Environ. Res. Public Health 2011, 8 1393 
 
Table 2. Cont. 
  Description of epidemiology 
study design & subjects 
 
Method of exposure 
assessment 
Biological sample  
and (immune 
biomarkers employed) 
Key findings and evaluation  
of concordance 
 
 Cross-sectional;  children   
with asthma (n = 33) vs. 
health controls 
Questionnaire Exhaled  breath 
condensate (IFN-γ, 
TNF-α, IL-2, IL-4,  
IL-5, IL-10) 
Cytokine levels low but 
detectable; processing method 
needs improvement  
(Robroeks et al. 2006) [22] 
Asthma Case-control  retrospective; 
adults ages 20–79  
(n = 3,443) 
Questionnaire and 
blood evaluation: 
ethanol levels, 
CDT1, GGT, 
ASAT, ALAT 
Peripheral Blood; 
(serum IgE) 
Positive associations between 
alcohol consumption and  
total IgE serum levels in  
atopic subjects  
(Friedrich et al. 2008) [41] 
 
Chronic 
Obstructive 
Pulmonary 
Disease 
(COPD) 
 
 
 
Cross-sectional; patients  
with COPD (n = 35),  
non-smokers (n = 18),  
and smokers (n = 20) 
Questionnaire; 
criteria for  
non-smokers was 
normal spirometry 
results 
Induced sputum 
(differential cell 
counts; CXCL9, 
CXCL10, CXCL11, 
and CCL5 by ELISA)
CXCR3 and CCL5 increased 
in COPD patients compared 
with non smokers  
(Costa, et al. 2008) [42] 
Cross-sectional; patients  
with COPD (n = 26),  
smokers (n = 19),  
healthy non-smokers (n = 5) 
Questionnaire; 
history of smoking
Bronchial Alveolar 
Lavage (BAL) and 
peripheral blood (CD3, 
CD4, CD8, CD45RA, 
CD25, CD69) 
Increased CD8 and 
CD4+CD25+ in COPD BAL 
samples  
(Smyth et al. 2007) [43] 
Cross-sectional; COPD  
(n = 30), divided into two 
categories: Forced-expiratory 
volume in 1 second (FEV1) 
<50% and >50% 
Questionnaire; 
smoking status 
Induced sputum  
(IL-6, IL-8 and  
TNF-α) 
Mean levels of three cytokines 
elevated in severe vs.  
moderate COPD  
(Hacievliyagil et al. 2005) [44]
1 carbohydrate-deficient transferring (CDT), gamma-glutamyl transferase (GGT), aspartate-amino transferase 
(ASAT), alanine-amino transferase (ALAT) are biomarkers of recent and long-term exposure to alcohol [45]. 
Bronchial biopsies from asthmatic patients reveal an infilitration of eosinophils, activated mucosal 
mast and T cells whereas in COPD eosinophils are largely absent but neutrophils are present in large 
numbers [46]. Also, in COPD, there is also an imbalance of the CD4+/CD8+ T-lymphocyte ratio in the 
lungs with CD8 predominating [43]. The inflammatory state of the lung is thought to be maintained 
through recruitment of macrophages and lymphocytes [34]. Increased expression of chemokine 
receptor CXCR3 on macrophages, and its ligand CXCL10 has been observed in patients with   
COPD [47]. In support of these findings, Costa et al. reported that in addition to CXCR3, chemokine 
receptors CXCL9, CXCL10, and CXCL11 were elevated in COPD, compared to non-smokers [42]. 
The levels of inflammatory cytokines (IL-6, IL-8, and TNF-α) are also elevated in COPD [44]. The 
cumulative data available for this disease is in part due to the extensive validation efforts by 
researchers to standardize sample collection methods and biomarker endpoints analysis [48]. 
Asthma is characterized by chronic inflammation in the airways and the presence of a 
predominance of CD4
+ T-helper 2 cells that secrete IL-4, IL-5, and IL-13 cytokines [49,50]. Th2 cells 
contribute to the immunopathogenesis of asthma by recruiting eosinophils and mast cells to the Int. J. Environ. Res. Public Health 2011, 8 1394 
 
airways [51,52] and by inducing B-cells to produce immunoglobulin E antibodies [53]. Increased 
levels of IFN-γ also have been reported in cases of severe asthma that could involve CD8
+ T cells [54]. 
In childhood, a major risk factor for the development of persistent asthma is atopy, which is defined  
by the presence of IgE to common inhalant allergens such as house dust mite [55]. Polymorphisms  
in CD14, a membrane receptor for bacterial components, have been linked to atopy [56]. In a 
comprehensive study by Heaton et al. [38], multiple immune markers were used to differentiate 
between various airway disease phenotypes in children. The authors reported that atopic children were 
more likely to have increased T-helper 2 (Th2) cytokines such as interleukin IL-4, IL-5, IL-13   
whereas children with bronchial hyper-reactivity were more likely to have elevated IFN-γ, a Th1 
cytokine [38]. The associations of Th1/Th2 are not consistent for all allergic disorders. For example, 
Kaneko et al. [57] reports that atopic dermatitis (AD) is associated with increased IL-4 Th2 cells, 
whereas Machura et al. [58] report that children with AD have significantly lower IL-4 Th2 cells and 
TNF-α Th1 cells and, therefore, no distinct bias towards Th1 or Th2 profiles.  
Hollams et al. (2009) [59] sought to identify biomarkers associated with asthma phenotypes in 
teenagers, particularly atopic asthma, and to identify markers that aid in discriminating between atopic 
subjects at high versus low risk of asthma. In a cohort of 1380 14-year olds, clinical history as 
well as measurement of circulating and/or inflammatory markers (e.g., eosinophils, IgE, cytokine 
measurements) and in vitro innate and adaptive immune functions (e.g., house dust mite (HDM) T-cell 
responses) were evaluated. HDM-induced cytokine expression of IL-5, IL-9, IL-10, IL-13, and IFN-γ 
were significantly elevated in teens with asthma. Due to the redundancy of the immune system, for 
example IL-5, IL-9 and IL-13 contribute to the Th2 response and generation of IgE, therefore it is 
important to examine changes in several cytokines simultaneously rather than in isolation. 
5. Emerging Methods 
Advances in technology have introduced a variety of “omic” approaches to study human diseases 
and identify new biomarkers [60]. Interrogation of DNA (genomics) reflects genetic variability, 
mRNA (also genomics, sometimes called transcriptomics) displays changes in gene expression, 
proteins (proteomics) represent cellular and enzymatic changes (proteomics), and metabolites 
(metabonomics) highlight the physiological endpoints [9]. Toxicogenomics, the identification of 
specific gene expression profiles in biological systems associated with xenobiotic exposure, is 
increasingly being applied in immunotoxicity assessments [61]. For example, children with the   
TGF-β1-509TT genotype are at increased risk of asthma when they are exposed to maternal smoking 
in utero or to traffic-related emissions [62]. In immunotoxicology studies, microarrays have been used 
mainly in drug development to model pharmacodynamic effects of pharmaceuticals [63]. 
Multiparameter flow cytometry can also provide insight into cell maintenance and function; these 
include immunophenotyping, cell cycle and proliferation markers, indicators of cell injury and death, 
intracellular functional and biochemical analyses [64]. 
Immunomics involves the integration of the immune-related genomics and proteomics; this 
approach will help in the synthesis of vast, and sometimes redundant, information. It is of particular 
relevance to the field of environmental health research in which biological data is collected from 
subjects to evaluate the associations between environmental exposures (e.g., xenobiotics, allergens) Int. J. Environ. Res. Public Health 2011, 8 1395 
 
and disease outcomes (e.g., asthma, COPD). For example, single nucleotide polymorphisms (SNPs) in 
immune-related genes suspected to be involved in disease pathology can be evaluated together with the 
protein expression of that gene. As it is unlikely that a complete data set of cytokines, for example, can 
be gathered from one study, inputing the limited data set into an interactive map of the cytokine 
pathway could prove useful for interpreting the net immune response. This would be particularly 
useful in instances where there is redundancy or overlap in the functions of cytokines and/or immune 
cells. Diaz-Ramos et al. (2010) [65] recently described the development of a comprehensive 
immunome that identified 1,015 genes expressed in immune cells or lymphoid tissues that correspond 
to proteins located on the plasma membrane. The identification of an immunomic profile will 
contribute to the compilation of “fingerprints” of dysregulated immunity; these will prove useful in the 
investigation of environmental health diseases and the process of linking environmental exposures to 
immune disorders.  
6. Discussion and Conclusions 
Immunoinformatics, including the software and hardware capable of synthesizing this information 
will enable researchers to visualize global changes in protein expression profiles relevant markers  
of interest [66-68]. Research areas of immunoinformatics include (1) allergy prediction,   
(2) understanding of immune-related genes, (3) study of genes and their expressions in healthy and 
diseased states, (4) T- and B- cell epitope prediction, and in silico vaccination [66]. Yan (2010) [69] 
has summarized the resources available on the genetic variation on the immune system. Integration of 
accumulating data will be an important step in identifying a useful immunologic marker. This can be 
accomplished by an integrated evaluation of multiple data sets obtained (biological, epidemiological, 
statistical, clinical trial) and evaluating the risk-benefit evidence. [70]. For example, the use of a scale 
to rate the level of evidence provided (study design, target outcome, and statistical evaluation), with 
level 1 the strongest evidence and 5 the weakest; 2 represents a potential surrogate marker. The criteria 
listed in this rating system were used to evaluate biomarkers for the immune disorder rheumatoid 
arthritis and the marker CD68, specific for macrophages, was designated a level three (epidemiology 
studies were not considered to be statistically powered), whereas the soluble marker C-reactive protein was 
deemed difficult to rank [71]. Weak clinical study design, including power and duration, was cited as the 
main limitation of this study [72]. Several factors that contribute to the variability of immune 
parameters are host factors and assay variation, and both of these can be addressed when designing the 
study. Host factors (e.g., sex, age, ethnicity/geography, nutrition) [73] and exposure factors   
(e.g., chemicals, bioaerosols, season, smoking, alcohol etc.) and disease states (e.g. leukemia, asthma, 
infections, etc.) also contribute to the variability of immune biomarkers [74,75]. For example, when 
lymphocyte subsets were analyzed in children who ranged in age from newborns to 18 years old, age 
was found to be an important factor in distributions of cell types [76]. Stress [77] and socioeconomic 
status [78] also impact the status of asthma in children and adolescents, identified by changes in 
cytokine biomarkers (IL-4, IL-5, and IFN-γ). In adults, alcohol intake has been associated with 
increased serum IgE levels [41].  The intra-individual variability should be low, compared to the   
inter-individual variability. Additionally, the effect of other host factors such as age, gender, stress, Int. J. Environ. Res. Public Health 2011, 8 1396 
 
exercise, and smoking on biomarker measurement should also be well-characterized. The markers 
should be analytically detectable and reproducible in the same laboratory and in others.  
In conclusion, the use of immune biomarkers in human clinical trials and molecular epidemiology 
of environmental health can facilitate a better understanding of the mechanisms that underlie 
associations between environmental exposures and immune-mediated disorders, such as cancer, 
asthma, and autoimmune disorders. An integrated approach that incorporates host and environmental 
factors will be particularly important in the development and application of immunologic biomarkers 
in public health research.  
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